Arrowhead Pharmaceuticals Inc.
Most Recent
ContraVir Stock Rose on Clinical Trial Progress Report
ContraVir Pharmaceuticals is focused on the development of antiviral therapies with a special focus on the development of anti-HBV therapies.
How Analysts View Arrowhead Pharmaceuticals
In Q2, Arrowhead Pharmaceuticals reported revenues of $48.15 million—a YoY rise of 7,305.95%—ahead of the consensus estimate by $5.19 million.
Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.
Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date
On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30.
Why Arbutus Biopharma Stock Plunged 24.4% Today
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09.
How Is Arrowhead Pharmaceuticals Stock Positioned?
On October 4, Arrowhead Pharmaceuticals entered into a license and collaboration agreement with Janssen Pharmaceuticals.
Why Arrowhead Pharmaceuticals Stock Is Skyrocketing Today
Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10.
Analysts’ Ratings for Sorrento and Its Peers in March 2018
Of the two analysts covering Sorrento Therapeutics in March 2018, one analyst has given it a “strong buy” recommendation.
Taking Stock of Arrowhead Pharmaceuticals’ Financial Performance
In 2017, Arrowhead Pharmaceuticals (ARWR) generated revenue of $31.4 million compared to $158,000 in 2016. This increase was attributable to the upfront payments Arrowhead received from Amgen.
What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.
Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.
Analysts’ Recommendations for Arrowhead and Its Peers
Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them.
